Received Apr 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 233FT | — |
pediatric dose of Engerix-B to a 21 y/o patient; pediatric dose of Engerix-B to a 21 y/o patient; This non-serious case was reported by a nurse via call center representative and described the occurrence of underdose in a 21-year-old female patient who received HBV (Engerix B pediatric) (batch number 233FT, expiry date 12-DEC-2025) for prophylaxis. On 09-APR-2025, the patient received Engerix B pediatric. On 09-APR-2025, an unknown time after receiving Engerix B pediatric, the patient experienced underdose (Verbatim: pediatric dose of Engerix-B to a 21 y/o patient) and adult use of a child product (Verbatim: pediatric dose of Engerix-B to a 21 y/o patient). The outcome of the underdose and adult use of a child product were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 10-APR-2025 The nurse requested data on the administration of pediatric dose of Engerix b to a 21ear year old patient which led to underdose and adult use of child product.